>Mercado global de células estaminais pluripotentes induzidas (iPSCs), por fonte celular (células da pele e células sanguíneas), tipo (IPSCs humanos e IPSCs de ratinho), produto (instrumentos, consumíveis e kits e serviços), aplicações (investigação académica, medicina regenerativa , Terapia celular, Rastreio Toxicológico, Descoberta e Desenvolvimento de Fármacos, Modelação de Doenças, Banco de Células Estaminais , Bioimpressão 3D e Outros), Utilizador Final (Empresas Farmacêuticas e de Biotecnologia, Laboratórios de Investigação, Laboratórios de Diagnóstico e Outros) , Canal de Distribuição (Concurso Directo e Vendas a Retalho) , País (EUA, Canadá, México, Alemanha, Reino Unido, Itália, França, Espanha, Suíça, Rússia, Turquia, Bélgica, Holanda e resto da Europa, Japão, China, Coreia do Sul, Índia, Austrália, Singapura, Tailândia, Malásia, Indonésia, Filipinas e restante Ásia-Pacífico, Brasil, Argentina e restante América do Sul, África do Sul, Egito, Arábia Saudita, Emirados Árabes Unidos, Israel e restante do Médio Oriente e África) – Tendências e previsões do setor para 2029
Análise e insights de mercado: Mercado global de células estaminais pluripotentes induzidas (iPSCs)
Espera-se que o mercado global de células estaminais pluripotentes induzidas (iPSCs) ganhe crescimento de mercado no período de previsão de 2022 a 2029. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 9,9% no período de previsão de 2022 a 2029 e deverá atingir os 2.081,08 milhões de dólares até 2029. O aumento das atividades de investigação sobre terapias com células estaminais atua como motor para o crescimento do mercado de células estaminais pluripotentes induzidas (iPSCs).
As células estaminais pluripotentes induzidas são tipos de células derivadas de tecidos somáticos adultos e reprogramadas com um conjunto de genes e fatores para ganhar natureza pluripotente. Certos genes e fatores são adicionados para atingir propriedades definidas das células estaminais embrionárias . As células pluripotentes induzidas, sendo quase idênticas às células dadoras, auxiliam na modelação de doenças. Os retrovírus são comummente utilizados como vetores para reprogramar células estaminais pluripotentes induzidas. As principais aplicações das células estaminais pluripotentes induzidas são na modelação de doenças, descoberta e desenvolvimento de fármacos, estudos de toxicidade e terapias genéticas. São muito utilizados em tratamentos de doenças cardiovasculares , diabetes mellitus e diversos tipos de cancro. As células estaminais pluripotentes induzidas pelo homem mostram as propriedades relevantes da doença, uma vez que transportam o genótipo específico da doença, permitindo assim novas opções terapêuticas de forma específica para o doente.
A crescente adoção da terapia com células estaminais, o crescimento do setor da biotecnologia com melhores investimentos e o aumento da prevalência de doenças crónicas atuam como impulsionadores do mercado das células estaminais pluripotentes induzidas (iPSCs). Os outros fatores que deverão impulsionar o crescimento do mercado global de células estaminais pluripotentes induzidas (iPSCs) incluem a vasta gama de aplicações clínicas das células estaminais pluripotentes induzidas e os avanços tecnológicos emergentes das iPSCs.
No entanto, fatores como o elevado custo associado às terapias com células estaminais e a disponibilidade de alternativas para o tratamento de tumores estão a dificultar o crescimento do mercado global de células estaminais pluripotentes induzidas (iPSCs). Por outro lado, o número crescente de produtos em pipeline, o aumento do interesse pela medicina personalizada e o aumento dos gastos em saúde atuam como uma oportunidade para o crescimento do mercado global de células estaminais pluripotentes induzidas (iPSCs). As regras e regulamentações rigorosas e a instabilidade genómica da IPSC são o principal desafio de mercado enfrentado no mercado global de células estaminais pluripotentes induzidas (iPSCs).
O relatório de mercado de células estaminais pluripotentes induzidas (iPSCs) fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentos de mercado, aprovações de produtos, decisões de estratégia, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado de células estaminais pluripotentes induzidas (iPSCs), contacte a Data Bridge Market Research para obter um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito e dimensão do mercado de células estaminais pluripotentes induzidas (iPSCs)
O mercado das células estaminais pluripotentes induzidas (iPSCs) está segmentado com base na fonte celular, tipo, produto, aplicações, utilizadores finais e canal de distribuição. determinar a sua aplicação principal áreas e a diferença nos seus mercados-alvo.
O mercado global de células estaminais pluripotentes induzidas (iPSCs) está categorizado em seis segmentos notáveis com base na fonte celular, tipo, produto, aplicações, utilizadores finais e canal de distribuição.
- Com base na fonte celular, o mercado global de células estaminais pluripotentes induzidas (iPSCs) está segmentado em células da pele e células sanguíneas. Em 2022, prevê-se que o segmento das células da pele domine o mercado, uma vez que a obtenção de células da pele como os fibroblastos e os queratinócitos é menos invasiva, menos dolorosa e facilmente obtida.
- Com base no tipo, o mercado global de células estaminais pluripotentes induzidas (iPSCs) está segmentado em IPSCs humanos e IPSCs de ratinhos. Em 2022, prevê-se que o segmento das IPSCs humanas domine o mercado, uma vez que as células somáticas humanas são amplamente utilizadas em terapias celulares, modelação de doenças, descoberta de fármacos e, entre outros, como controlos.
- Com base no produto, o mercado global de células estaminais pluripotentes induzidas (iPSCs) está segmentado em instrumentos, consumíveis, kits e serviços. Em 2022, prevê-se que o segmento de consumíveis e kits domine o mercado devido à utilização generalizada de kits de células estaminais pluripotentes induzidas em testes toxicológicos.
- Com base na aplicação, o mercado global de células estaminais pluripotentes induzidas (iPSCs) está segmentado em investigação académica, medicina regenerativa, terapia celular, rastreio toxicológico, descoberta e desenvolvimento de medicamentos, modelação de doenças, banco de células estaminais, bioimpressão 3D e outros. Em 2022, prevê-se que o segmento da descoberta e desenvolvimento de medicamentos domine o mercado, uma vez que as células estaminais estão a ganhar mais atenção na descoberta de novas opções terapêuticas para o surgimento de diversas doenças crónicas e infeciosas.
- Com base nos utilizadores finais, o mercado global de células estaminais pluripotentes induzidas (iPSCs) está segmentado em empresas de biotecnologia e farmacêuticas, laboratórios de investigação, laboratórios de diagnóstico e outros. Em 2022, prevê-se que o segmento das empresas farmacêuticas e de biotecnologia domine o mercado à medida que fabricam e desenvolvem vários kits de células estaminais e tecnologia de serviços utilizando células estaminais pluripotentes induzidas para diversas doenças.
- Com base no canal de distribuição, o mercado global de células estaminais pluripotentes induzidas (iPSCs) está segmentado em concurso direto e vendas a retalho. Em 2022, prevê-se que o segmento de licitação direta domine o mercado devido à manutenção estável da qualidade dos produtos diretamente das unidades fabris.
Análise ao nível do país do mercado de células estaminais pluripotentes induzidas (iPSCs)
O mercado das células estaminais pluripotentes induzidas (iPSCs) é analisado e são fornecidas informações sobre o tamanho do mercado por país, fonte de células, tipo, produto, aplicações, utilizadores finais e canal de distribuição, conforme mencionado acima.
Os países abrangidos no relatório do mercado de células estaminais pluripotentes induzidas (iPSCs) são os EUA, Canadá e México, Reino Unido, Alemanha, França, Espanha, Itália, Países Baixos, Suíça, Rússia, Turquia, Áustria, Irlanda e Resto da Europa, China , Coreia do Sul, Japão, Índia, Austrália, Singapura, Malásia, Indonésia, Tailândia, Filipinas e resto da Ásia-Pacífico, África do Sul, Arábia Saudita, Emirados Árabes Unidos, Israel, Egipto e resto do Médio Oriente e África, Brasil, Argentina, e restante América do Sul.
Prevê-se que o segmento de células da pele nos EUA da região norte-americana cresça com a maior taxa de crescimento no período de previsão de 2022 a 2029 devido ao aumento da utilização da tecnologia de células estaminais. O segmento das células da pele na Alemanha está a dominar o mercado europeu devido ao aumento de casos de doenças crónicas e à elevada adoção de fontes de células estaminais para melhores terapias. A China lidera o crescimento do mercado Ásia-Pacífico e o segmento das células da pele está a dominar neste país devido ao número crescente de centros de biotecnologia e atividades de investigação.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e disponibilidade de marcas globais e os desafios enfrentados devido à concorrência grande ou escassa de marcas locais e nacionais, o impacto dos canais de vendas são considerados, ao mesmo tempo que fornece uma análise de previsão dos dados do país.
O crescimento das atividades estratégicas dos principais players do mercado para aumentar a consciencialização sobre o tratamento com células estaminais pluripotentes induzidas (iPSCs) está a impulsionar o crescimento do mercado das células estaminais pluripotentes induzidas (iPSCs).
O mercado das células estaminais pluripotentes induzidas (iPSCs) também fornece análises de mercado detalhadas para o crescimento de cada país num mercado específico. Além disso, fornece informações detalhadas sobre a estratégia dos intervenientes no mercado e a sua presença geográfica. Os dados estão disponíveis para o período histórico de 2011 a 2020.
Cenário competitivo e análise da quota de mercado das células estaminais pluripotentes induzidas (iPSCs)
O panorama competitivo do mercado de células estaminais pluripotentes induzidas (iPSCs) fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura e amplitude do produto, domínio de aplicação, curva de segurança da tecnologia. Os dados fornecidos acima estão apenas relacionados com o foco da empresa relacionado com o mercado de células estaminais pluripotentes induzidas (iPSCs).
As principais empresas que negoceiam com células estaminais pluripotentes induzidas (iPSCs) são a Thermo Fisher Scientific Inc., a FUJIFILM Corporation, a LumaCyte, a Horizon Discovery Ltd., a Hopstem Biotechnology LLC., a Takara Bio Inc., a Cell Applications, Inc., a Citius Pharmaceuticals, Inc., Lonza., Evotec SE., Fate Therapeutics, Universal Cells Inc. (Uma empresa Astellas), Axol Bioscience Ltd., R&D Systems, Inc., Charles River Laboratories International, Inc., Corning Incorporated, REPROCELL Inc., Applied StemCell., Merck KGaA, GeneCopoeia, Inc. e entre outros players nacionais. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos contratos e acordos são também iniciados pelas empresas de todo o mundo que também estão a acelerar o mercado das células estaminais pluripotentes induzidas (iPSCs).
Por exemplo,
- Em fevereiro de 2021, a Thermo Fisher Scientific Inc. anunciou que tinha ganho seis prémios nos CMO Leadership Awards anuais. Os prémios, atribuídos pela Life Science Leader e pela Outsourced Pharma, reconhecem os principais parceiros de fabrico por contrato avaliados por empresas biofarmacêuticas e de biotecnologia. Estima-se que este reconhecimento previu fortalecer a presença da empresa no mercado global e levar ao aumento do crescimento da empresa nos próximos anos.
- Em junho de 2020, a LumaCyte colaborou com a Catalent, fornecedora global de tecnologias avançadas de entrega, desenvolvimento e soluções de fabrico para medicamentos, produtos biológicos, terapias celulares e genéticas e produtos de saúde de consumo. Esta colaboração ajudou na expansão do produto de tecnologia de células estaminais da empresa, Radiance, e na sua aplicação.
A colaboração, o lançamento de produtos, a expansão do negócio, a premiação e o reconhecimento, as joint ventures e outras estratégias do player de mercado estão a melhorar a presença da empresa no mercado das bombas de infusão veterinária, o que também proporciona o benefício para o crescimento do lucro da organização .
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CELL SOURCE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 GLOBAL MEDICAL CARTS MARKET: REGULATIONS
5.1 REGULATION IN U.S.
5.2 REGULATION IN CANADA
5.3 REGULATION IN EUROPE
5.4 REGULATION IN INDIA
5.5 REGUALTION IN JAPAN
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS
6.1.2 EMERGING TECHNOLOGICAL ADVANTAGES OF IPSCS
6.1.3 RISING PREVALENCE OF SEVERAL CHRONIC DISEASES
6.1.4 INCREASING ADOPTION OF STEM CELL THERAPY
6.1.5 GROWING BIOTECHNOLOGY SECTOR WITH BETTER INVESTMENT
6.2 RESTRAINT
6.2.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES AND LARGE-SCALE APPLICATIONS OF IPSCS
6.2.2 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT
6.2.3 ADVERSE EFFECTS OF STEM CELL TRANSPLANTS
6.3 OPPORTUNITIES
6.3.1 INCREASING NUMBER OF PIPELINE PRODUCTS
6.3.2 INCREASING INTEREST OF PERSONALIZED MEDICINE
6.3.3 SURGE IN HEALTHCARE EXPENDITURE
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 GENOMIC INSTABILITY OF IPSCS IS THE KEY MARKET CHALLENGE
6.4.2 LACK OF SKILLED PROFESSIONALS
6.4.3 STRINGENT REGULATORY FRAMEWORK
7 IMPACT OF COVID-19 ON THE GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY CHAIN
7.4 STRATEGIC DECISIONS BY MANUFACTURERS
7.5 CONCLUSION
8 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE
8.1 OVERVIEW
8.2 SKIN CELLS
8.2.1 FIBROBLAST
8.2.2 KERATINOCYTES
8.2.3 ADIPOSE DERIVED STEM CELLS
8.2.4 HEPATOCYTES
8.2.5 MELANOCYTES
8.2.6 NEURAL STEM CELLS
8.2.7 OTHERS
8.3 BLOOD CELLS
8.3.1 PERIPHERAL BLOOD
8.3.2 CORD BLOOD ENDOTHELIAL CELLS
8.3.3 CORD BLOOD STEM CELLS
8.3.4 OTHERS
9 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE
9.1 OVERVIEW
9.2 HUMAN IPSCS
9.3 MOUSE IPSCS
10 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT
10.1 OVERVIEW
10.2 CONSUMABLES & KITS
10.2.1 REPROGRAMMING KITS
10.2.2 MEDIA
10.2.3 TRANSFECTION KITS
10.2.4 CELL IDENTIFICATION KITS
10.2.5 ACCESSORIES
10.2.6 OTHERS
10.3 SERVICES
10.4 INSTRUMENTS
10.4.1 IMAGING SYSTEMS
10.4.2 ELECTROPORATION DEVICE
10.4.3 INCUBATORS
10.4.4 OTHERS
11 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 DRUG DISCOVERY AND DEVELOPMENT
11.3 ACADEMIC RESEARCH
11.4 DISEASE MODELLING
11.5 CELLULAR THERAPY
11.6 REGENERATIVE MEDICINE
11.7 TOXICOLOGY SCREENING
11.8 STEM CELL BANKING
11.9 3D BIOPRINTING
11.1 OTHERS
12 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER
12.1 OVERVIEW
12.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
12.3 RESEARCH LABORATORIES
12.4 DIAGNOSTIC LABORATORIES
12.5 OTHERS
13 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION
14.1 OVERVIEW
14.2 NORTH AMERICA
14.2.1 U.S.
14.2.2 CANADA
14.2.3 MEXICO
14.3 EUROPE
14.3.1 GERMANY
14.3.2 FRANCE
14.3.3 U.K.
14.3.4 ITALY
14.3.5 RUSSIA
14.3.6 SPAIN
14.3.7 TURKEY
14.3.8 NETHERLANDS
14.3.9 SWITZERLAND
14.3.10 BELGIUM
14.3.11 REST OF EUROPE
14.4 ASIA-PACIFIC
14.4.1 CHINA
14.4.2 JAPAN
14.4.3 INDIA
14.4.4 SOUTH KOREA
14.4.5 AUSTRALIA
14.4.6 SINGAPORE
14.4.7 THAILAND
14.4.8 MALAYSIA
14.4.9 INDONESIA
14.4.10 PHILIPPINES
14.4.11 REST OF ASIA-PACIFIC
14.5 SOUTH AMERICA
14.5.1 BRAZIL
14.5.2 ARGENTINA
14.5.3 REST OF SOUTH AMERICA
14.6 MIDDLE EAST AND AFRICA
14.6.1 SOUTH AFRICA
14.6.2 SAUDI ARABIA
14.6.3 UAE
14.6.4 EGYPT
14.6.5 ISRAEL
14.6.6 REST OF MIDDLE EAST AND AFRICA
15 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 FUJIFILM CORPORATION
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.1.5.1 ACQUISITION
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.2.5.1 EVENT
17.2.5.2 ACQUISITION
17.3 LONZA.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.3.5.1 EXPANSION
17.4 MERCK KGAA
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.4.5.1 AGREEMENT
17.5 EVOTEC SE.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.5.5.1 AGREEMENT
17.5.5.2 COLLABORATION
17.6 APPLIED STEMCELL.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENTS
17.6.3.1 PRODUCT LAUNCH
17.7 AXOL BIOSCIENCE LTD.
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.7.3.1 MERGER
17.7.3.2 PRODUCT LAUNCH
17.8 CELL APPLICATIONS, INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.8.3.1 PARTNERSHIP
17.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENT
17.9.4.1 ACQUISITION
17.1 CITIUS PHARMACEUTICALS, INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.10.3.1 AGREEMENT
17.11 CORNING INCORPORATED
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.11.4.1 AGREEMENT
17.12 FATE THERAPEUTICS
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.12.3.1 CLINICAL TRIAL
17.13 GENECOPOEIA, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 HOPSTEM BIOTECHNOLOGY LLC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.14.3.1 PARTNERSHIP
17.15 HORIZON DISCOVERY LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 LUMACYTE
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.16.3.1 COLLABORATION
17.17 R & D SYSTEMS, INC.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 REPROCELL INC.
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENTS
17.18.3.1 COLLABORATION
17.18.3.2 FACILITY EXPANSION
17.18.3.3 SERVICE LAUNCH
17.19 TAKARA BIO INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.19.4.1 NEW FACILITY LAUNCH
17.2 UNIVERSAL CELLS INC. (AN ASTELLAS COMPANY)
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.20.4.1 ACQUISITION
18 QUESTIONNAIRE
19 RELATED REPORTS
Lista de Tabela
TABLE 1 NEW CANCER CASES, AGES 85+, IN THE U.S.
TABLE 2 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 3 GLOBAL SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 GLOBAL SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 5 GLOBAL BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 GLOBAL BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 7 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 GLOBAL HUMAN IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 GLOBAL MOUSE IPSCS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 11 GLOBAL CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 GLOBAL CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 13 GLOBAL SERVICES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 GLOBAL INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 GLOBAL INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 16 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 GLOBAL DRUG DISCOVERY AND DEVELOPMENT IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 GLOBAL ACADEMIC RESEARCH IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 GLOBAL DISEASE MODELLING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 GLOBAL CELLULAR THERAPY IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 GLOBAL REGENERATIVE MEDICINE IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 GLOBAL TOXICOLOGY SCREENING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 GLOBAL STEM CELL BANKING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 GLOBAL 3D BIOPRINTING IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 GLOBAL OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 27 GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 GLOBAL RESEARCH LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 GLOBAL DIAGNOSTIC LABORATORIES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 GLOBAL OTHERS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 32 GLOBAL DIRECT TENDER IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 GLOBAL RETAIL SALES IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 46 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 47 U.S. SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 48 U.S. BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 49 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 51 U.S. INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 52 U.S. CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 53 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 54 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 U.S. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 56 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 57 CANADA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 58 CANADA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 59 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 61 CANADA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 62 CANADA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 63 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 64 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 65 CANADA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 66 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 67 MEXICO SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 68 MEXICO BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 69 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 70 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 71 MEXICO INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 72 MEXICO CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 73 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 75 MEXICO INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 76 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 77 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 78 EUROPE SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 79 EUROPE BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 80 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 82 EUROPE INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 83 EUROPE CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 84 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 85 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 86 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 87 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 88 GERMANY SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 89 GERMANY BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 90 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 92 GERMANY INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 93 GERMANY CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 94 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 95 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 GERMANY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 98 FRANCE SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 99 FRANCE BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 100 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 102 FRANCE INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 103 FRANCE CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 104 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 105 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 106 FRANCE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 107 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 108 U.K. SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 109 U.K. BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 110 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 112 U.K. INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 113 U.K. CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 114 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 115 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 U.K. INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 118 ITALY SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 119 ITALY BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 120 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 122 ITALY INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 123 ITALY CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 124 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 125 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 126 ITALY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 127 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 128 RUSSIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 129 RUSSIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 130 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 132 RUSSIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 133 RUSSIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 134 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 135 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 136 RUSSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 137 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 138 SPAIN SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 139 SPAIN BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 140 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 141 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 142 SPAIN INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 143 SPAIN CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 144 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 145 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 146 SPAIN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 147 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 148 TURKEY SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 149 TURKEY BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 150 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 152 TURKEY INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 153 TURKEY CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 154 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 155 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 156 TURKEY INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 157 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 158 NETHERLANDS SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 159 NETHERLANDS BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 160 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 162 NETHERLANDS INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 163 NETHERLANDS CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 164 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 165 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 166 NETHERLANDS INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 167 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 168 SWITZERLAND SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 169 SWITZERLAND BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 170 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 172 SWITZERLAND INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 173 SWITZERLAND CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 174 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 175 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 176 SWITZERLAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 177 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 178 BELGIUM SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 179 BELGIUM BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 180 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 182 BELGIUM INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 183 BELGIUM CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 184 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 185 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 186 BELGIUM INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 187 REST OF EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 188 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 189 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 190 ASIA-PACIFIC SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 191 ASIA-PACIFIC BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 192 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 194 ASIA-PACIFIC INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 195 ASIA-PACIFIC CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 196 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 197 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 198 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 199 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 200 CHINA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 201 CHINA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 202 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 204 CHINA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 205 CHINA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 206 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 207 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 208 CHINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 209 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 210 JAPAN SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 211 JAPAN BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 212 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 213 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 214 JAPAN INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 215 JAPAN CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 216 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 217 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 218 JAPAN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 219 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 220 INDIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 221 INDIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 222 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 224 INDIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 225 INDIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 226 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 227 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 228 INDIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 229 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 230 SOUTH KOREA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 231 SOUTH KOREA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 232 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 233 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 234 SOUTH KOREA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 235 SOUTH KOREA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 236 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 237 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 238 SOUTH KOREA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 239 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 240 AUSTRALIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 241 AUSTRALIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 242 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 243 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 244 AUSTRALIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 245 AUSTRALIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 246 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 247 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 248 AUSTRALIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 249 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 250 SINGAPORE SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 251 SINGAPORE BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 252 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 253 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 254 SINGAPORE INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 255 SINGAPORE CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 256 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 257 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 258 SINGAPORE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 259 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 260 THAILAND SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 261 THAILAND BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 262 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 263 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 264 THAILAND INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 265 THAILAND CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 266 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 267 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 268 THAILAND INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 269 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 270 MALAYSIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 271 MALAYSIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 272 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 273 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 274 MALAYSIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 275 MALAYSIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 276 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 277 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 278 MALAYSIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 279 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 280 INDONESIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 281 INDONESIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 282 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 283 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 284 INDONESIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 285 INDONESIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 286 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 287 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 288 INDONESIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 289 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 290 PHILIPPINES SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 291 PHILIPPINES BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 292 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 293 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 294 PHILIPPINES INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 295 PHILIPPINES CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 296 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 297 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 298 PHILIPPINES INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 299 REST OF ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 300 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 301 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 302 SOUTH AMERICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 303 SOUTH AMERICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 304 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 305 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 306 SOUTH AMERICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 307 SOUTH AMERICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 308 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 309 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 310 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 311 BRAZIL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 312 BRAZIL SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 313 BRAZIL BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 314 BRAZIL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 315 BRAZIL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 316 BRAZIL INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 317 BRAZIL CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 318 BRAZIL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 319 BRAZIL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 320 BRAZIL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 321 ARGENTINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 322 ARGENTINA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 323 ARGENTINA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 324 ARGENTINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 325 ARGENTINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 326 ARGENTINA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 327 ARGENTINA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 328 ARGENTINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 329 ARGENTINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 330 ARGENTINA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 331 REST OF SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 332 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 333 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 334 MIDDLE EAST AND AFRICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 335 MIDDLE EAST AND AFRICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 336 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 337 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 338 MIDDLE EAST AND AFRICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 339 MIDDLE EAST AND AFRICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 340 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 341 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 342 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 343 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 344 SOUTH AFRICA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 345 SOUTH AFRICA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 346 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 347 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 348 SOUTH AFRICA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 349 SOUTH AFRICA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 350 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 351 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 352 SOUTH AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 353 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 354 SAUDI ARABIA SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 355 SAUDI ARABIA BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 356 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 357 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 358 SAUDI ARABIA INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 359 SAUDI ARABIA CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 360 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 361 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 362 SAUDI ARABIA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 363 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 364 UAE SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 365 UAE BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 366 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 367 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 368 UAE INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 369 UAE CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 370 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 371 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 372 UAE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 373 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 374 EGYPT SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 375 EGYPT BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 376 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 377 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 378 EGYPT INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 379 EGYPT CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 380 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 381 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 382 EGYPT INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 383 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 384 ISRAEL SKIN CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 385 ISRAEL BLOOD CELLS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
TABLE 386 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 387 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 388 ISRAEL INSTRUMENTS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 389 ISRAEL CONSUMABLES & KITS IN INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 390 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 391 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 392 ISRAEL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 393 REST OF MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE, 2020-2029 (USD MILLION)
Lista de Figura
FIGURE 1 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION
FIGURE 2 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SEGMENTATION
FIGURE 11 THE WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS (IPSC) ARE EXPECTED TO DRIVE THE GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SKIN CELLS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET
FIGURE 16 PREVALENCE OF CHRONIC DISEASES
FIGURE 17 NUMBER OF PEOPLE WITH DIABETES (MILLION) AMONG AGES 20–79 YEARS
FIGURE 18 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2021
FIGURE 19 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, 2020-2029 (USD MILLION)
FIGURE 20 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, CAGR (2022-2029)
FIGURE 21 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE, LIFELINE CURVE
FIGURE 22 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, 2021
FIGURE 23 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 24 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 25 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 26 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, 2021
FIGURE 27 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 28 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 29 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 30 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2021
FIGURE 31 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 32 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 33 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 34 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, 2021
FIGURE 35 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 36 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 39 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 40 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 41 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SNAPSHOT (2021)
FIGURE 43 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY REGION (2021)
FIGURE 44 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY REGION (2022 & 2029)
FIGURE 45 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY REGION (2021 & 2029)
FIGURE 46 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE (2022-2029)
FIGURE 47 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SNAPSHOT (2021)
FIGURE 48 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021)
FIGURE 49 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 50 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 51 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE (2022-2029)
FIGURE 52 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SNAPSHOT (2021)
FIGURE 53 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021)
FIGURE 54 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 55 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 56 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE (2022-2029)
FIGURE 57 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SNAPSHOT (2021)
FIGURE 58 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021)
FIGURE 59 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 60 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 61 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE (2022-2029)
FIGURE 62 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SNAPSHOT (2021)
FIGURE 63 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021)
FIGURE 64 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 65 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 66 SOUTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE (2022-2029)
FIGURE 67 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: SNAPSHOT (2021)
FIGURE 68 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021)
FIGURE 69 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 70 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 71 MIDDLE EAST AND AFRICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: BY CELL SOURCE (2022-2029)
FIGURE 72 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY SHARE 2021 (%)
FIGURE 73 NORTH AMERICA INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY SHARE 2021 (%)
FIGURE 74 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY SHARE 2021 (%)
FIGURE 75 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
